Biotech and Pharmaceuticals Pharmaceuticals

  • Roche to Maintain Growth With New Drug: CEO

    A new cancer drug being trialed by Swiss Drugmaker Roche Holding will present a key opportunity for the company in the coming months, Roche CEO Severin Schwan told CNBC Tuesday.

  • A Smart Bet on Johnson & Johnson?

    Johnson & Johnson reported better-than-expected quarterly results on Tuesday, as prescription drug sales rebounded with the help of newer products and jitters about medical device sales proved unfounded.

  • Bulls Want a Lift From Allergan

    Option traders are finding a new favorite in Botox maker Allergan.

  • Bausch & Lomb: Vision for a Public Offering?

    Brent Saunders, Bausch & Lomb CEO, discusses his firm's dedication to eye and vision care, and whether the time is right for his company to return to the public markets.

  • Fungal Meningitis Death Toll Reaches 8

    According to the CDC, the death toll has now reached 8 from a contaminated steroid used to treat back pain that came from a Massachusetts Compounding pharmacy. The next update from the CDC will be at 2PM EST today.

  • Why Investors Like Pharma Stocks

    Pharmaceuticals continue to be an attractive sector for earnings and dividend growth, and CNBC's Seema Mody reports on how companies like Pfizer are faring.

  • Larry the Cable Guy

    I asked Larry about all kinds of topics, from the presidential debates to the U.S. economy to his own personal investments.

  • Hong Kong's IPO Market in 'Deep Recession': Pro

    Francis Lun, Managing Director at Lyncean Holdings says Hong Kong's IPO market is in a deep recession, hurt by a slump in China and the euro zone. He adds the market's recovery will be slow.

  • Healthcare cost

    TheStreet.com reports on Sarepta Therapeutics and the outstanding results from the eteplirsen study in Duchenne muscular dystrophy announced today.

  • Healthcare cost

    Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.

  • Hunt For Yield... In Pharma?

    CNBC's Seema Mody shares several dividend plays for investors seeking yield in the pharma sector.

  • Biotech

    TheStreet reports that Peregrine stock plunged when company reported discrepancies in the cancer drug bavituximab study.

  • Biotech

    Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.

  • Arena Pharmaceuticals

    Vivus announced the commercial launch of its weight-loss pill Qsymia Monday, beating rival Arena Pharmaceuticals to first reach the bulging waistbands of obese Americans.  TheStreet.com reports.

  • Abbott Laboratories

    Option action lit up yesterday in Abbott Laboratories, which has been a solid performer for the last year.

  • AstraZeneca Poaches Genentech Boss From Roche

    AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.

  • Healthcare cost

    Idenix Pharmaceuticals shares fell 10 percent Monday after the U.S. Food and Drug Administration placed a second of the company's experimental hepatitis C drugs on clinical hold due to heart safety concerns. TheStreet.com reports.

  • Eli Lilly & Co. corporate headquarters stand in Indianapolis, Indiana, U.S., on Monday, May 21, 2012.

    A treatment for Alzheimer's disease from drugmaker Eli Lilly yielded promising signs in late-stage research, even though the drug failed to slow mental decline in two separate studies of patients with mild-to-moderate cases of the mind-robbing condition.

  • Merck

    Now is the time to own stocks with big dividends, one analyst says. In health care, that means large cap pharmaceuticals. TheStreet.com reports.

  • Apple Store

    Apple has quietly told its store workers to match discounts on the iPhone 4 and iPhone 4S from approved major retailers and carriers like Sprint Nextel, which is currently offering a $50 break. Apple won’t offer the discounts automatically; customers have to ask.